title: Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation.
abstract: We report the development of a double-cycle elutriation (DCE) technique separating 3 or greater logs of T cells from a stem-cell-enriched marrow fraction and the results of phase I T-cell depletion studies with HLA-disparate related bone marrow transplantation (BMT) donors in two patient groups. In group 1, 10 patients with refractory hematopoietic malignancies received combination chemotherapy, total body irradiation (TBI), and immunosuppression (pre- and post-BMT), and hematopoietic rescue with a marrow transplant, depleted of T cells by elutriation. Potentially to promote engraftment and a graft-versus-leukemia (GVL) effect, 0.5 to 0.75 x 10(5) T cells/kg were added back. All 10 patients engrafted. Five patients developed acute graft-versus-host disease (GVHD; four grade II, one grade III) and two subsequently developed chronic GVHD. Two patients have relapsed (median follow-up, 206 days; range, 46 to 1,035). Four patients died of BMT-related complications (three of infection, one of veno-occlusive disease [VOD]). Four patient are disease-free survivors (median follow-up, 960 days; range, 670 to 1,035). Group 2 included five infants, four with congenital lymphohematopoietic deficiencies and one with refractory acute lymphocytic leukemia (ALL). In these infants, busulfan and increased cyclophosphamide were substituted for TBI. Only the ALL patient received added T cells. Three patients engrafted: one has stable mixed chimerism, one relapsed with ALL, and one rejected the marrow. One patient had primary autologous recovery, while another failed to engraft. None developed GVHD. We conclude that, in this setting of HLA-disparate BMT with post-BMT antithymocyte globulin (ATG) and corticosteroids, DCE significantly depletes T cells from the marrow and that a defined number of T cells can be added without the occurrence of severe GVHD.
authors.affiliation: Department of Hematology/Oncology, Children's National Medical Center, Washington, DC 20010.
authors.forename: R R
authors.initials: RR
authors.lastname: Quinones
authors.forename: R H
authors.initials: RH
authors.lastname: Gutierrez
authors.forename: P A
authors.initials: PA
authors.lastname: Dinndorf
authors.forename: R E
authors.initials: RE
authors.lastname: Gress
authors.forename: A B
authors.initials: AB
authors.lastname: Ney
authors.forename: B
authors.initials: B
authors.lastname: Taylor
authors.forename: S
authors.initials: S
authors.lastname: Karandish
authors.forename: C S
authors.initials: CS
authors.lastname: Carter
authors.forename: N L
authors.initials: NL
authors.lastname: Luban
authors.forename: G H
authors.initials: GH
authors.lastname: Reaman
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D008212:Lymphocyte Depletion / Q000379:methods*; D008297:Male; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000166:cytology*
chemical_list: D006680:HLA Antigens